TGFB1 and systemic sclerosis: Recently, changes to the glycolytic phenotype have been identified in a number of other autoimmune7, 8, 9 and fibrotic disorders,10, 11 including TGF‐β‐mediated GLUT1 up‐regulation12—however, this is the first time metabolic reprogramming has been characterized in SSc.